Next Issue
Previous Issue

E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Table of Contents

Mar. Drugs, Volume 2, Issue 2 (June 2004), Pages 55-82

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Readerexternal link to open them.
View options order results:
result details:
Displaying articles 1-3
Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle Identification of Renieramycin A as an Antileishmanial Substance in a Marine Sponge Neopetrosia sp.
Mar. Drugs 2004, 2(2), 55-62; doi:10.3390/md202055
Received: 15 October 2003 / Accepted: 15 March 2004 / Published: 25 May 2004
Cited by 17 | PDF Full-text (160 KB) | HTML Full-text | XML Full-text
Abstract
The newly developed assay system using recombinant Leishmania amazonensis expressing enhanced green fluorescent protein (La/egfp) has been applied to the screening of Japanese marine sponges for antileishmanial activity. Bioassay-guided fractionation of an active sponge Neopetrosia sp. afforded an active compound which
[...] Read more.
The newly developed assay system using recombinant Leishmania amazonensis expressing enhanced green fluorescent protein (La/egfp) has been applied to the screening of Japanese marine sponges for antileishmanial activity. Bioassay-guided fractionation of an active sponge Neopetrosia sp. afforded an active compound which was identified as renieramycin A by spectroscopic analysis. It inhibited La/egfp with an IC50 value of 0.2 μg/mL. Full article
Open AccessArticle Fucoxanthin and Its Metabolites in Edible Brown Algae Cultivated in Deep Seawater
Mar. Drugs 2004, 2(2), 63-72; doi:10.3390/md202063
Received: 21 April 2004 / Accepted: 8 May 2004 / Published: 25 May 2004
Cited by 42 | PDF Full-text (173 KB) | HTML Full-text | XML Full-text
Abstract Three metabolites of fucoxanthin were isolated from a brown alga, Scytosiphon lomentaria, and the structure of a new compound was determined by NMR. The content of fucoxanthin, a biologically active carotenoid, in four edible brown algae, cultivated in deep seawater, was studied. Full article

Review

Jump to: Research

Open AccessReview Drugs and Cosmetics from the Sea
Mar. Drugs 2004, 2(2), 73-82; doi:10.3390/md202073
Received: 27 April 2004 / Accepted: 13 May 2004 / Published: 25 May 2004
Cited by 52 | PDF Full-text (86 KB) | HTML Full-text | XML Full-text
Abstract
The marine environment is a rich source of both biological and chemical diversity. This diversity has been the source of unique chemical compounds with the potential for industrial development as pharmaceuticals, cosmetics, nutritional supplements, molecular probes, fine chemicals and agrochemicals. In recent years,
[...] Read more.
The marine environment is a rich source of both biological and chemical diversity. This diversity has been the source of unique chemical compounds with the potential for industrial development as pharmaceuticals, cosmetics, nutritional supplements, molecular probes, fine chemicals and agrochemicals. In recent years, a significant number of novel metabolites with potent pharmacological properties has been discovered from the marine organisms. Although there are only a few marine-derived products currently on the market, several robust new compounds derived from marine natural products are now in the clinical pipeline, with more clinical development. While the marine world offers an extremely rich resource for novel compounds, it also represents a great challenge that requires inputs from various scientific areas to bring the marine chemical diversity up to its therapeutic potential. Full article

Journal Contact

MDPI AG
Marine Drugs Editorial Office
St. Alban-Anlage 66, 4052 Basel, Switzerland
marinedrugs@mdpi.com
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18
Editorial Board
Contact Details Submit to Marine Drugs
Back to Top